ライフサイエンスコーパス: phase III study

1 o be further confirmed in a large randomized phase III study.

2 benefit but need to be confirmed in a larger phase III study.

3 id hemorrhage, but has yet to be tested in a phase III study.

4 ommended dose for evaluation in a randomized phase III study.

5 on the same schedule, in this international phase III study.

6 mia (CML) were evaluated in an international phase III study.

7 mized, placebo-controlled, active-comparator phase III study.

8 as an international, randomized, open-label, phase III study.

9 ma were treated at a single institution on a phase III study.

10 IIB is a randomized, open-label, multicenter phase III study.

11 ified end points justifying advancement to a phase III study.

12 This was a multicenter randomized phase III study.

13 TISSE was a randomized, open-label, adaptive phase III study.

14 apecitabine were included in this randomized phase III study.

15 ngoing IFM/Dana-Farber Cancer Institute 2009 phase III study.

16 , double-blind, double-dummy, parallel-group phase III study.

17 ts are being investigated further in a large phase III study.

18 r, with a safety profile comparable to prior phase III studies.

19 safety profile comparable with that in prior phase III studies.

20 port end-of-phase II decisions and design of phase III studies.

21 nic symptoms, were enrolled in 2 consecutive phase III studies.

22 he main endpoint to measure effectiveness in phase III studies.

23 phase II studies and underpowered or flawed phase III studies.

24 ariety of clinical trials, including several phase III studies.

25 -satoreotide trizoxetan to be used in future phase III studies.

26 ategy in axSpA, and several new molecules in phase III studies.

27 ing randomized evidence, and examine ongoing phase III studies.

28 the efficacy of LDV/SOF regimens in the ION phase III studies.

29 ter transfer protein inhibitors are still in phase III studies.

30 d phase II study and is preferred for future phase III studies.

31 essed by simulating multiple replicas of the phase III studies.

32 and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments.

33 or recurrent endometrial cancer (aEC) in the phase III Study 309/KEYNOTE-775.

34 In a phase III study, 411 healthy individuals from 19 US site

35 In this multicenter, double-blind, phase III study, 418 patients with previously untreated,

36 In this open-label, multicenter phase III study, 87 patients with PI aged >/=2 years rec

37 ouble-blind, placebo-controlled, multicenter phase III study, a total of 52 patients with inoperable

38 spective of their JAK2 mutation status, in 2 phase III studies against placebo (COMFORT-I) and best a

39 Numerous ongoing phase III studies aim to further evaluate tarlatamab's c

40 This double-blind, phase III study aimed to demonstrate that sunitinib plus

41 This phase III study (ALLY-3) evaluated the 12-week regimen o

42 rongly influenced by results of a randomized phase III study among recurrent patients as well as furt

43 To be considered for a phase III study, an arm had to achieve a 2-year progress

44 ible and relevant primary end point for both phase III studies and phase II studies where a delay in

45 We aimed to confirm these results in a phase III study and investigated a potential clinical be

46 hase II study), latency to persistent sleep (phase III study), and circadian phase shifting (phase II

47 tested in sarcoma patients in a phase II and phase III study, and was shown to prolong progression-fr

48 Complementing these phase III studies are a number of innovative phase II st

49 h remains investigational however, and these phase III studies are critical.

50 Larger phase III studies are needed to ascertain if these acute

51 Phase III studies are needed to define the role of vacci

52 Phase III studies are now beginning to establish firmly

53 sults with cabozantinib are encouraging, and phase III studies are ongoing.

54 A pivotal phase II and a confirmatory phase III study are ongoing.

55 ation therapy and was well tolerated in each Phase III study, as well as in the pooled analysis, rega

56 s retrospective analysis of three randomized phase III studies assessed the prognostic and predictive

57 This phase III study assessed efficacy and safety of oral, su

58 This phase III study assessed the efficacy of vandetanib vers

59 This phase III study assessed the impact of postoperative adj

60 C30) data were collected prospectively in a phase III study assessing gemcitabine and cisplatin vers

61 lticenter, double-blind, placebo-controlled, phase III study at 107 sites in 10 countries.

62 Setup of a phase III study at a major cooperative oncology group is

63 Median calendar days to activate a phase III study at CALGB was 580 days (range, 295 to 1,2

64 In the phase III study AVF2107g, bevacizumab (BV) demonstrated

65 uximab 800/600 mg/m(2) is being evaluated in phase III studies based on clinical benefit observed in

66 requent treatment-emergent adverse events in phase III studies but were not treatment limiting.

67 nt a robust surrogate of protection in early Phase III studies, but vaccines provide protection prior

68 have been shown to provide benefit in IBD in phase III studies by blocking other antiinflammatory pat

69 These considerations led to a randomized phase III study by the International Berlin-Frankfurt-Mu

70 ith stage III CC included in the IDEA France phase III study (ClinicalTrials.gov identifier: NCT00958

71 ty, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard r

72 omized, controlled, multicenter, open-label, phase III study compared docetaxel versus paclitaxel in

73 This randomized, multicenter, phase III study compared doxorubicin and docetaxel (AT)

74 This open-label, randomized, phase III study compared oral and IV topotecan in patien

75 This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisp

76 This prospective multicenter phase III study compared the efficacy and safety of a tr

77 This phase III study compared the efficacy and safety of beva

78 This phase III study compared the efficacy and safety of beva

79 This phase III study compared the efficacy and safety of gemc

80 This phase III study compared the safety and efficacy of the

81 This phase III study compared the time to progression (TTP) o

82 ce/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, predn

83 Phase III studies comparing imatinib with nilotinib or d

84 g-term survival and toxicity of a randomized phase III study comparing cisplatin alone with cisplatin

85 Purpose A phase III study comparing eribulin with dacarbazine in p

86 otype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel p

87 erformed an open-label randomized controlled phase III study comparing treatment outcome and toxicity

88 ods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group syst

89 ble-blind, placebo-controlled parallel group phase III study conducted in Germany (21 sites), in adul

90 In the phase III study COU-AA-301, abiraterone acetate (AA) plu

91 Validation included analyses of phase III study data sets to determine if the same mutat

92 Recently reported, placebo-controlled phase III studies demonstrate a meaningful progression-f

93 Data from phase III studies demonstrate that with SOF-based regime

94 Pneumonia Treatment In the Community (OPTIC) phase III study demonstrated noninferiority of omadacycl

95 This large, phase III study demonstrates comparable efficacy of DA Q

96 on is further complicated by the fact that a phase III study designed to compare secondary hormonal t

97 the lack of consensus for ideal phase II and phase III study designs, several trials for diverse comp

98 This phase III study documents a role for gemcitabine in adva

99 icenter, randomized, controlled, open-label, phase III study, eligible patients age 18 years and olde

100 TS AND METHODS This multicenter, open-label, phase III study enrolled 676 chemotherapy-naive patients

101 s and Methods This randomized, double-blind, phase III study enrolled patients with histologically co

102 In this phase III study, eribulin was not shown to be superior t

103 nt 52-week, double-blind, placebo-controlled phase III study evaluated induction and maintenance trea

104 This phase III study evaluated overall survival (OS) and othe

105 This placebo-controlled phase III study evaluated telotristat ethyl in this sett

106 This phase III study evaluated the efficacy and safety of ear

107 Ten phase III studies evaluating the role of IFN-alpha2 in 1

108 ent-I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with

109 A recent phase III study evaluating the combination of lenalidomi

110 eport the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of li

111 We report the results of OPUS-2, a phase III study evaluating the efficacy and safety of li

112 Following completion of phase III studies, eventual new drug application approva

113 The result of a third phase III study examining the effect of tissue factor pa

114 w-up awaits confirmation in the larger-scale phase III study (EXCITE trial) currently in progress.

115 Although a recent phase III study failed to demonstrate any protective eff

116 d phase II trials; although the registration phase III study failed to meet its accrual goals, it did

117 Recent phase III studies, following angiography-based phase I a

118 CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS

119 We will review ongoing phase III studies for patients in first clinical remissi

120 Future phase III studies for patients with AA may need to consi

121 ue, FTY720 (fingolimod), a drug currently in phase III studies for treatment of multiple sclerosis, h

122 size and survival time distributions in the phase III study for both capecitabine and FU were consis

123 pancreatic NET, the longest OS reported in a phase III study for this population.

124 The randomized, open-label, phase III study FORWARD I compared MIRV and investigator

125 Furthermore, phase III studies frequently fail to achieve their plann

126 t antitumor response and overall survival in phase III studies from longitudinal tumor size data in p

127 This phase III study further investigated those findings.

128 This double blind, placebo controlled, phase III study had a screening period, a 2 week dose ti

129 A set of confirmatory phase III studies has been initiated to determine whethe

130 Recent clinical evidence from phase III studies has shown that nintedanib has signific

131 randomized, double-blind, placebo-controlled phase III study has since been conducted in patients wit

132 of rheumatoid arthritis - over the past year phase III studies have demonstrated impressive improveme

133 In metastatic colorectal cancer, phase III studies have demonstrated the superiority of f

134 hoice of nonvalidated scientific targets for phase III studies have hampered progress and created mis

135 Phase III studies have yet to be undertaken for these no

136 Recent results from a phase III study have indicated that treatment of patient

137 ies, including data derived from prospective phase III studies, have linked adrenal-permissive allele

138 but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the tran

139 aluations, with four positive reports in six phase III studies identified.

140 analyzed five randomized, placebo-controlled phase III studies in 4,205 patients with breast, colorec

141 evaluated as a monotherapy in two randomized phase III studies in advanced NSCLC.

142 Accrual to national phase III studies in early disease is now critical and s

143 Phase III studies in patients with multiple myeloma and

144 l compared with docetaxel in two independent phase III studies in previously treated patients with ad

145 a represent the longest follow-up to date in phase III studies in uHCC.

146 enter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C

147 BENEFIT is a randomized 3 year, phase III study in adults receiving a kidney transplant

148 alization (MMSE) in a randomized prospective phase III study in mCRC.

149 oxacin-treated patients) was observed in the phase III study in patients with community-acquired bact

150 ed with single-agent rituximab in an ongoing phase III study in relapsed FL.

151 oGRession in Multiple SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosi

152 All eyes from the VISTA Phase III study in the IAI groups imaged with the Cirrus

153 th FCAS, and the data led to the design of a phase III study in this patient population.

154 VIKING-3 is a single-arm, open-label phase III study in which therapy-experienced adults with

155 We did a phase III study in which we used a (123)I-FP-CIT SPECT s

156 The recent completion of several phase III studies, including those evaluating octreotide

157 In a parallel phase III study, Intergroup N9741, oxaliplatin plus fluo

158 This phase III study investigated the effect of combining oxa

159 This placebo-controlled phase III study investigated the effect on survival of g

160 This phase III study investigated the efficacy and safety of

161 This phase III study investigated two sequences: folinic acid

162 This phase III study investigated whether continuation mainte

163 nd, randomized, parallel-group, multicentre, phase III study investigating the efficacy and safety of

164 Newer phase III studies involve the use of new systemic agents

165 Results of Phase III studies involving a large number of Alzheimer'

166 A confirmatory phase III study is currently underway.

167 The study findings suggest that a definitive phase III study is feasible but highlights important con

168 lignant glioma and suggest that a randomized phase III study is indicated.

169 A phase III study is ongoing.

170 his was a post hoc analysis of the Edaravone Phase III Study MCI186-19 ('Study 19') to examine the ut

171 umor response and survival in an independent phase III study (n = 1,000 replicates) of capecitabine v

172 The OlympiAD Phase III study (NCT02000622) established the clinical b

173 A global phase III study (NCT02312206) has been initiated.

174 f genotypes in patients from 2 multinational phase III studies of adefovir dipivoxil.

175 Phase III studies of an oral, live, pentavalent, human-b

176 There are no published randomized phase III studies of bladder, cervical, endometrial, and

177 By contrast, two phase III studies of GVAX, an allogeneic tumor cell vacc

178 We discuss the phase II and phase III studies of hepatic-arterial infusion therapy,

179 Phase III studies of intravenous amivantamab demonstrate

180 es in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or re

181 These data form the basis of a planned Phase III study of (68)Ga-THP PSMA in patients with pros

182 A recent randomized phase III study of 719 de novo liver transplant recipien

183 MONARCH 3 is a randomized, double-blind, phase III study of abemaciclib plus NSAI (anastrozole or

184 patients entered into a multi-institutional Phase III study of adjuvant therapy for colon cancer.

185 phase II study of cetuximab and a randomized phase III study of bevacizumab.

186 Using data from the 1-year phase III study of deferasirox, including volumes of tra

187 sier Oncology Group designed this randomized phase III study of gemcitabine plus cisplatin compared w

188 The phase III study of hydroxyurea in infants (BABY HUG) has

189 A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab ver

190 A phase III study of IL-2 is now warranted.

191 On the basis of these observations, a phase III study of low-dose rivaroxaban as adjunctive th

192 s participating in a double blind randomized Phase III study of neoadjuvant endocrine therapy.

193 This phase III study of pafolacianine met its primary efficac

194 A phase III study of palliative liver RT is planned.

195 d the diagnostic performance and safety in a phase III study of patients with SSTR-expressing NETs.

196 ed to findings from the KEYNOTE-177 trial (A Phase III Study of Pembrolizumab [MK-3475] vs Chemothera

197 andomized, double-blind, placebo-controlled, phase III study of rituximab therapy.

198 REACH2 is a phase III study of ruxolitinib versus best available the

199 A global phase III study of S-1 plus cisplatin versus fluorouraci

200 A phase III study of TH-302 is ongoing (NCT01440088).

201 In a post hoc analysis of data from a phase III study of the effects of teduglutide on patient

202 This first phase III study on a topical inhibitor of corneal angiog

203 long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarb

204 In this phase III study patients were randomized to receive 6 su

205 andomized, double-blind, placebo-controlled, phase III study, patients received intravenous docetaxel

206 In this phase III study, patients were randomly assigned to open

207 In this open-label randomized phase III study, patients with metastatic hormone-sensit

208 In a randomized, open-label, multicenter, phase III study, patients with previously untreated pred

209 As part of phase III studies, plasma and fecal samples were analyze

210 e recently published results of a randomized phase III study prompted an update of this guideline.

211 This multicenter, open-label, phase III study randomly assigned patients in a 1:2 rati

212 wo symptomatic infants with SMA1 enrolled in phase III studies received onasemnogene abeparvovec.

213 This randomized, controlled, multicenter, phase III study recruited patients age 18 years or older

214 The CONKO-003 phase III study reported a survival benefit with second-

215 In the meantime, Phase III study results suggest investigational epicutan

216 OG 8802, 9506, 9706, 9906, and 0233) and one phase III study (RTOG 8903).

217 In this global, randomized, phase III study, SG was compared with physician's choice

218 lar endothelial growth factor antibody, in a phase III study, showed significantly improved overall a

219 Phase III studies support chemoimmunotherapy as the init

220 In the phase III study, tasimelteon improved sleep latency, sle

221 This phase III study tested the hypothesis that the CA-125-sp

222 Definitive phase III studies testing the hypothesis that this appro

223 itudinal tumor size models and data from two phase III studies that compared bevacizumab plus chemoth

224 Recently, data from two randomized phase III studies that compared docetaxel-based chemothe

225 We report a multicenter phase III study that compared pegylated liposomal doxoru

226 randomized, double-blind, placebo-controlled phase III study that enrolled men or women with advanced

227 A-BRAVE is a phase III study that randomly assigned patients with hig

228 m a theoretical perspective or in randomized phase III studies, there are little data to demonstrate

229 In the absence of a phase III study, this new combined treatment should be r

230 Given the premature termination of the phase III study, this supports the need for further defi

231 Two completed randomized phase III studies to be reported in mid-2004 will more d

232 nt populations, mitigating the need for full Phase III studies to test the hypothesis.

233 (A phase III study to compare SonoVue(R) enhanced myocardia

234 then undertook a multicentric international phase III study to compare three and five cycles of the

235 Phase III study to confirm a trend observed in a previou

236 efficacy and physiological mechanism, and a phase III study to confirm efficacy of the melatonin ago

237 A phase III study to evaluate the longer term effects of o

238 We designed a prospective, randomized, phase III study to test additional interventions to impr

239 randomized, double-blind, placebo-controlled phase III study to test whether the administration of in

240 The IELSG-19 phase III study, to our knowledge, was the first such st

241 In phase III studies, treatment with the once-daily fixed-d

242 in sepsis, the positive outcome of a recent phase III study using activated protein C (APC) has led

243 A pivotal phase III study using Sipuleucel-T, an autologous prosta

244 This open, randomized, phase III study was carried out in 71 centers.

245 A randomized, open-label, phase III study was conducted in 16 institutions through

246 of historical etoposide-platinum controls, a phase III study was conducted to compare pemetrexed-carb

247 ), this randomized, double-blind, controlled phase III study was conducted to confirm the efficacy an

248 This phase III study was conducted to confirm the phase II re

249 A double-blind, placebo-controlled phase III study was performed to assess whether basilixi

250 This phase III study was performed to confirm preclinical stu

251 randomized, double-blind, placebo-controlled phase III study was performed to establish definitively

252 the Children's Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing l

253 The objective of this phase III study was to determine the efficacy, safety, a

254 A phase III study was undertaken to evaluate the safety an

255 Oncology Group study AHOD0031, a randomized phase III study, was designed to evaluate the role of ea

256 Thirteen phase III studies were activated by CALGB during the stu

257 Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-

258 A larger phase III study will be necessary to determine whether t

259 A series of phase III studies with these antibodies and direct tyros

260 We undertook an open-label phase III study with recruitment between March 1, 2004,

261 rt of 287 patients treated in a multicenter, phase III study with single-agent irinotecan administere

262 In this randomized double-blind phase III study, women with high-risk, hormone receptor-